In a report released today, Oliver McCammon from LifeSci Capital maintained a Buy rating on Celcuity (CELC – Research Report), with a price target of $27.00.
Oliver McCammon has given his Buy rating due to a combination of factors, primarily focusing on the promising developments in Celcuity’s ongoing clinical trials. The VIKTORIA-1 trial, which is testing the pan-PI3K/mTOR inhibitor gedatolisib in combination with Pfizer’s Ibrance and fulvestrant, is a significant driver of this optimism. The anticipated topline data from the PIK3CA WT cohort in Q2 2025 is expected to provide crucial insights into the efficacy of this treatment combination for ER+ breast cancer patients.
Additionally, Celcuity’s strategic positioning in the breast cancer treatment landscape, particularly with its focus on patients who have been exposed to CDK4/6 inhibitors, is seen as a positive indicator of potential success. The company’s ability to enroll patients with measurable disease in the VIKTORIA-1 study further strengthens its clinical approach. These factors, combined with a manageable cash burn rate and a clear timeline for upcoming data readouts, contribute to McCammon’s positive outlook on Celcuity’s stock.
In another report released today, Needham also maintained a Buy rating on the stock with a $29.00 price target.